Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 10:30PM GMT
Release Date Price: R$40.28 (+1.71%)
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott from JPMorgan and I'm joined by my colleague, Robbie Marcus, and we're very pleased to be hosting a fireside chat with J&J this afternoon. From J&J, we have Jennifer Taubert, Chairman of the Pharmaceutical division; as well as Ashley McEvoy, Chairman of Medical Devices.

Before we start, I did have to read an FD disclosure quickly here, and then we'll jump into questions. Please be aware, some of the statements we're making today may be considered forward-looking or utilize non-GAAP measures. Please refer to J&J's SEC filings, particularly the 10-K, which discusses the risks and uncertainties around such forward-looking statements as well as the website, investor.jnj.com, for reconciliations of comparable GAAP measures. Finally, any performance metrics today may represent results through and including the third quarter of 2019.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot